About Deep Brain Stimulation for Parkinson's Disease
Sapiens initially focuses on Parkinson's disease (PD), a clinically proven and reimbursed DBS indication. World-wide, the number of patients with PD is estimated at 6 million; in about 1 million of these patients medication becomes inadequate and they can envisage DBS as adjunctive therapy. Today, only 80k patients, less than 8% of these patients, have been implanted with a DBS device. The current DBS world market for PD is 350 m€, growing with 16% CAGR. Key factors hampering faster growth are technology limitations resulting in too high adverse event rates and complicated procedures. Therefore, neurologists today only prescribe DBS as a last-resort therapy for late stage PD patients. Sapiens' programme of products will address these issues, which may accelerate market growth for PD, and other indications.

About Wellington Partners

Wellington Partners is one of the most successful pan-European venture capital firms. With some € 800 million under management and offices in London, Munich, Palo Alto and Zurich, the firm invests into companies throughout Europe that have the potential to become global leaders, in the areas of Digital Media, Technology and Life Sciences. Since 1998, Wellington has invested in more than 100 companies, including publicly traded Actelion, Wavelight, Evolva and XING and successful privately held companies like Alando (acquired by eBay) and Grandis (acquired by Novartis). For more information please visit www.wellington-partners.com.

About Edmond de Rothschild Investment Partners
Paris-based Edmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It has currently more than €800 million under management which is being invested primarily as life sciences venture capital and growth capital. Its Life Sciences team of seven professionals brings together over 30 years of experience in the Life Science industry and more than 50 years of private equity and venture capital experience. The team has approximately €220 million under management, and raised its most recent fund, € 150 million BioDiscovery 3 fund, in 2008. Edmond de Rothschild Investment Partners is part of La Compagnie Financière Edmond de Rothschild. For more information please visit: www.edrip.fr.

About LSP
LSP is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example, LSP was a founding investor in Movetis, Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With over EUR 500 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced specialist life-science investors. For more information please visit: www.lspvc.com.

About NeuroNexus
NeuroNexus is a neurotechnology company that develops and commercializes advanced brain interface devices for neurological and scientific applications. The company's proprietary technologies enables placement of sophisticated microelectronic and fluidic components on the surface of miniaturized brain probes that can be used to map brain function, to stimulate or modulate functions in specific brain regions, or to deliver drugs to precisely where they are needed in the brain. NeuroNexus is a leader in transforming ideas to technologies, and technologies to innovative products by working at the leading edges of neuroscience research, sensor technologies, and neurological applications. NeuroNexus is based in Ann Arbor, Michigan USA. For more information please visit www.neuronexus.com.

Back to HCB News

More HCB News